Clinical Data of 25 Patients With Myelopathy Associated With Human T-cell Lymphotropic Virus Type-1
| . | IDH/HAM/TSP Groupa (20 Cases) . | HAM/TSP Group (5 Cases) . | ||
|---|---|---|---|---|
| Time of breastfeedingb | 30 (0.4–60) | 24 (24–48) | ||
| Male/female ratio | 1/4 | 1/4 | ||
| Age at onset of neurological symptomsc | 9 (3–18) | 16 (11–18) | ||
| Age at HAM/TSP diagnosisc | 12,5 (4–20) | 17 (11–18) | ||
| Time of follow-up of HAM/TSPc | 8 (1–15) | 2 (1–3) | ||
| Duration of HAM/TSPd | 10 (2–20) | 3 (1–16) | ||
| Age at onset of IDH symptomsc | 2 (0.4–9) | … | ||
| Age at IDH diagnosisc | 8.5 (1–16) | … | ||
| Age at IDH remissionc,e | 17.50 (11–26) | … | ||
| Time between both diagnosesc | 4 (0–10) | … | ||
| Initial OMDS (grades)f | 1 (1–8) | 1 (1–2) | ||
| Final OMDS | 3 (1–9) | 3 (2–3) | ||
| Initial EDSS | 2 (1–7.5) | 1.5 (1–2.5) | ||
| Final EDSS | 3 (2–8) | 2.5 (1–3.5) | ||
| Neurological manifestations | Initial | At last visit | Initial | At last visitf |
| Sensory symptoms | 63% | 84% | 60% | 80% |
| Urinary complaints | 42% | 58% | 20% | 60% |
| Constipation | 37% | 74% | 20% | 40% |
| Piramidal signs | 84% | 89% | 80% | 80% |
| Gait disturbances | 79% | 100% | 40% | 100% |
| . | IDH/HAM/TSP Groupa (20 Cases) . | HAM/TSP Group (5 Cases) . | ||
|---|---|---|---|---|
| Time of breastfeedingb | 30 (0.4–60) | 24 (24–48) | ||
| Male/female ratio | 1/4 | 1/4 | ||
| Age at onset of neurological symptomsc | 9 (3–18) | 16 (11–18) | ||
| Age at HAM/TSP diagnosisc | 12,5 (4–20) | 17 (11–18) | ||
| Time of follow-up of HAM/TSPc | 8 (1–15) | 2 (1–3) | ||
| Duration of HAM/TSPd | 10 (2–20) | 3 (1–16) | ||
| Age at onset of IDH symptomsc | 2 (0.4–9) | … | ||
| Age at IDH diagnosisc | 8.5 (1–16) | … | ||
| Age at IDH remissionc,e | 17.50 (11–26) | … | ||
| Time between both diagnosesc | 4 (0–10) | … | ||
| Initial OMDS (grades)f | 1 (1–8) | 1 (1–2) | ||
| Final OMDS | 3 (1–9) | 3 (2–3) | ||
| Initial EDSS | 2 (1–7.5) | 1.5 (1–2.5) | ||
| Final EDSS | 3 (2–8) | 2.5 (1–3.5) | ||
| Neurological manifestations | Initial | At last visit | Initial | At last visitf |
| Sensory symptoms | 63% | 84% | 60% | 80% |
| Urinary complaints | 42% | 58% | 20% | 60% |
| Constipation | 37% | 74% | 20% | 40% |
| Piramidal signs | 84% | 89% | 80% | 80% |
| Gait disturbances | 79% | 100% | 40% | 100% |
Abbreviations: EDSS, expanded disability status score; HAM/TSP, HTLV-1–associated myelopathy/tropical spastic paraparesis; IDH, infective dermatitis associated with HTLV-1; OMDS, Osame motor disability score.
aThe dermatological aspects of 17 of these cases were described previously [8].
bValues expressed in median (months) and range.
cValues expressed in median (years) and range.
dDuration of HAM/TSP was calculated since onset of neurological manifestations.
eRemission occurred in only 8 patients.
fFour patients were not included, 3 of them due to the short follow-up and the other one due to the absence of motor disabilities.
Clinical Data of 25 Patients With Myelopathy Associated With Human T-cell Lymphotropic Virus Type-1
| . | IDH/HAM/TSP Groupa (20 Cases) . | HAM/TSP Group (5 Cases) . | ||
|---|---|---|---|---|
| Time of breastfeedingb | 30 (0.4–60) | 24 (24–48) | ||
| Male/female ratio | 1/4 | 1/4 | ||
| Age at onset of neurological symptomsc | 9 (3–18) | 16 (11–18) | ||
| Age at HAM/TSP diagnosisc | 12,5 (4–20) | 17 (11–18) | ||
| Time of follow-up of HAM/TSPc | 8 (1–15) | 2 (1–3) | ||
| Duration of HAM/TSPd | 10 (2–20) | 3 (1–16) | ||
| Age at onset of IDH symptomsc | 2 (0.4–9) | … | ||
| Age at IDH diagnosisc | 8.5 (1–16) | … | ||
| Age at IDH remissionc,e | 17.50 (11–26) | … | ||
| Time between both diagnosesc | 4 (0–10) | … | ||
| Initial OMDS (grades)f | 1 (1–8) | 1 (1–2) | ||
| Final OMDS | 3 (1–9) | 3 (2–3) | ||
| Initial EDSS | 2 (1–7.5) | 1.5 (1–2.5) | ||
| Final EDSS | 3 (2–8) | 2.5 (1–3.5) | ||
| Neurological manifestations | Initial | At last visit | Initial | At last visitf |
| Sensory symptoms | 63% | 84% | 60% | 80% |
| Urinary complaints | 42% | 58% | 20% | 60% |
| Constipation | 37% | 74% | 20% | 40% |
| Piramidal signs | 84% | 89% | 80% | 80% |
| Gait disturbances | 79% | 100% | 40% | 100% |
| . | IDH/HAM/TSP Groupa (20 Cases) . | HAM/TSP Group (5 Cases) . | ||
|---|---|---|---|---|
| Time of breastfeedingb | 30 (0.4–60) | 24 (24–48) | ||
| Male/female ratio | 1/4 | 1/4 | ||
| Age at onset of neurological symptomsc | 9 (3–18) | 16 (11–18) | ||
| Age at HAM/TSP diagnosisc | 12,5 (4–20) | 17 (11–18) | ||
| Time of follow-up of HAM/TSPc | 8 (1–15) | 2 (1–3) | ||
| Duration of HAM/TSPd | 10 (2–20) | 3 (1–16) | ||
| Age at onset of IDH symptomsc | 2 (0.4–9) | … | ||
| Age at IDH diagnosisc | 8.5 (1–16) | … | ||
| Age at IDH remissionc,e | 17.50 (11–26) | … | ||
| Time between both diagnosesc | 4 (0–10) | … | ||
| Initial OMDS (grades)f | 1 (1–8) | 1 (1–2) | ||
| Final OMDS | 3 (1–9) | 3 (2–3) | ||
| Initial EDSS | 2 (1–7.5) | 1.5 (1–2.5) | ||
| Final EDSS | 3 (2–8) | 2.5 (1–3.5) | ||
| Neurological manifestations | Initial | At last visit | Initial | At last visitf |
| Sensory symptoms | 63% | 84% | 60% | 80% |
| Urinary complaints | 42% | 58% | 20% | 60% |
| Constipation | 37% | 74% | 20% | 40% |
| Piramidal signs | 84% | 89% | 80% | 80% |
| Gait disturbances | 79% | 100% | 40% | 100% |
Abbreviations: EDSS, expanded disability status score; HAM/TSP, HTLV-1–associated myelopathy/tropical spastic paraparesis; IDH, infective dermatitis associated with HTLV-1; OMDS, Osame motor disability score.
aThe dermatological aspects of 17 of these cases were described previously [8].
bValues expressed in median (months) and range.
cValues expressed in median (years) and range.
dDuration of HAM/TSP was calculated since onset of neurological manifestations.
eRemission occurred in only 8 patients.
fFour patients were not included, 3 of them due to the short follow-up and the other one due to the absence of motor disabilities.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
